Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arnold Silva

Nephrology Meridian, ID Medical Doctor

NPI 1497790646 CMS profile 158060

3525 E Louise Dr Ste 195, Meridian, ID 83642

Open in the dashboard

General payments

$625,501

972 records reported · program years 2019–2025

Research payments

$1,529

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,454,176 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Arnold Silva of Meridian, ID is reported in the CMS Open Payments database as having received $625,501 across 972 general payments and $1,529 in research payments paid to them. Separately, studies naming them as principal investigator received $2,454,176 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103,928 174
2024 General $150,454 191
2023 General $71,308 126
2022 General $80,734 116
2021 General $102,003 134
2020 General $31,710 65
2019 General $85,365 166
2019 Research $1,529 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arnold Silva
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Arnold Silva were reported at $103,928. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Arnold Silva Nephrology median Middle half National median
2019 $85,365 $236 $90–$588 $163
2020 $31,710 $135 $46–$364 $114
2021 $102,003 $202 $67–$551 $132
2022 $80,734 $242 $77–$695 $149
2023 $71,308 $254 $84–$766 $160
2024 $150,454 $300 $99–$852 $164
2025 $103,928 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $115,122 120 payments
  2. AstraZeneca Pharmaceuticals LP $95,526 174 payments
  3. Retrophin, Inc. $90,829 202 payments
  4. GlaxoSmithKline, LLC. $51,563 83 payments
  5. Lilly USA, LLC $45,076 37 payments
  6. Amgen Inc. $43,363 78 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $37,876 45 payments
  8. Aurinia Pharma U.S., Inc. $30,742 36 payments
  9. Alexion Pharmaceuticals, Inc. $27,554 19 payments
  10. Apellis Pharmaceuticals, Inc. $20,527 21 payments
  11. Other $67,321 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $381,361 201 payments
  2. Travel and Lodging $103,681 273 payments
  3. Consulting Fee $83,689 66 payments
  4. Food and Beverage $26,522 415 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $26,157 9 payments
  6. Honoraria $4,020 1 payment
  7. Education $71 7 payments
Products named General payments · program years 2019–2025
  1. Kerendia $115,046 118 payments
  2. LOKELMA $94,588 157 payments
  3. JARDIANCE Diabetes $49,576 39 payments
  4. Parsabiv $39,801 64 payments
  5. JARDIANCE Diabetes $36,091 41 payments
  6. Filspari $30,798 60 payments
  7. LUPKYNIS $30,742 36 payments
  8. JESDUVROQ $29,033 27 payments
  9. Empaveli $15,384 14 payments
  10. ULTOMIRIS $9,818 8 payments
  11. Other $23,532 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,529 9 payments

Records

981 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record